Yury Rozenman | SVP of Business Development Life Sciences
Ada Health

Yury Rozenman is the Senior Vice President of Business Development at Ada Health. In this role, he leads the company's strategy, vision and oversees execution of all global business development activities in life sciences/pharmaceutical area. 
Yury has considerable experience of working in and consulting to the pharmaceutical & med tech industries, leading early and late phase clinical development programs, supporting new pharmaceutical product launches in respiratory and cardiovascular space, strategic business development & IP licensing.  Yury has over 10 years of experience within the industry in pharmaceutical research and development both as a project team leader and group research manager. He has also worked in diagnostics and medical devices and has been involved in the development and launch of world class drugs (Celebrex, Ambien, Cytotec) and diagnostic tests (Afib, OSA detection, HLA genotyping & WG sequencing).
Yury serves as an advisor to a number of start-ups such as AI first activity-based drug discovery, novel drug delivery company focused on needle-less injections and early stage start-up with unique new technology for continuous, passive and objective measurements of mental health. Yury is highly experienced in start-ups, fund raising and go to market strategy.
Prior to joining Ada Health, Yury was Senior Vice President of Life Sciences at Propeller Health (ResMed business). In this role Yury led significant projects focused on patient recruitment, engagement, education, intervention and adherence/compliance with top 25 pharmaceutical organizations in respiratory and rare disease areas such as cystic fibrosis, pulmonary hypertension and pulmonary fibrosis. 
With 25+ years’ experience in the pharma, biotech industry, high tech and telecom including roles at Searle/Pfizer, Applied Biosystems/Celera Genomics, DeShaw Ventures, IBM/PwC, BT Global Services, Qualcomm Life, Fitbit Health, Amazon and ResMed, I understand the power of new science & technology and what it takes for companies to pivot, transforming their mindsets, approaches, and business models to thrive in this new environment.